Asset profile
Lipovirtide
Peptide
Evidence outlook · lead readout
NCT06061536 · HIV
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06061536: The study was randomized and included an active DTG comparator, but it was open-label, enrolled 64 participants across four groups, and used viral suppression as a surrogate laboratory endpoint rather than a hard clinical outcome. Because the primary comparison and its statistical result are not available, the findings cannot be judged as having met or missed the endpoint.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.